加载中
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
前收盘价
US$0.6437
+US$0.0335 · +5.49%
盘后
US$0.668
+US$0.0243 · +3.78%
10月12日 19:12 ET
盘中时间采用ET。市场数据可能有所延迟。
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
日内区间
当前US$0.6437
52周区间
当前US$0.6437
盘中时间采用ET。市场数据可能有所延迟。
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
日内区间
当前US$0.6437
52周区间
当前US$0.6437
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 研究与开发 | 1029.26万 USD | 1867.63万 USD | 2170.83万 USD | 1638.72万 USD |
| 销售、一般及管理费用 | 1220.27万 USD | 648.45万 USD | 326.55万 USD | 381.96万 USD |
| 营业费用 | 2249.53万 USD | 2516.07万 USD | 2497.38万 USD | 2020.68万 USD |
| 利息收入 | 28.77万 USD | 22.23万 USD | 35.27万 USD | 2.7万 USD |
| 利息支出 | 2.03万 USD | −1.87万 USD | 4.36万 USD | 1.62万 USD |
| 折旧和摊销 | — | 2516.07万 USD | 2497.38万 USD | 2020.68万 USD |
| 营业利润 | −2249.53万 USD | −2516.07万 USD | −2497.38万 USD | −2020.68万 USD |
| 净利润 | −2222.79万 USD | −2728.53万 USD | −2474.46万 USD | −2015.94万 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$21.00
上涨空间 3162.39%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI43.68万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF16.12万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC2.21万0.00%13.17亿 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM1万0.01%1.16亿 USD0.73%US$15.8484-0.58%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
